| | | | | 1 | | | |
| | | | | 6 | | | |
| | | | | 9 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 21 | | | |
| | | | | 23 | | | |
| | | | | 31 | | | |
| | | | | 32 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 36 | | | |
| | | | | A-1 | | |
Name
|
| |
Age
|
| |
Position(s)
|
| |
Served as a
Director Since |
|
John Koconis | | |
51
|
| | Chief Executive Officer, President and Chairman of the Board | | |
2020
|
|
Zachary Rome | | |
37
|
| | Chief Operating Officer, Executive Vice President, Director and Secretary | | |
2020
|
|
David Cohen, M.D. | | |
56
|
| | Director | | |
2020
|
|
Lubor Gaal, Ph.D. | | |
53
|
| | Director | | |
2020
|
|
Gianluca Pirozzi, M.D., Ph.D. | | |
44
|
| | Director | | |
2020
|
|
Edward J. Sitar | | |
60
|
| | Director | | |
2020
|
|
Name
|
| |
Age
|
| |
Position(s)
|
| |
Served as an
Officer Since |
|
John Koconis | | |
51
|
| |
Chief Executive Officer President and Chairman of the Board
|
| |
2020
|
|
Joseph Lucchese | | |
54
|
| | Chief Financial Officer, Executive Vice President and Treasurer | | |
2020
|
|
Alan Mendelsohn, M.D. | | |
58
|
| | Chief Medical Officer and Executive Vice President | | |
2021
|
|
Zachary Rome | | |
37
|
| |
Chief Operating Officer, Executive Vice President, Secretary and Director
|
| |
2020
|
|
Name and principal position
|
| |
Year
|
| |
Salary ($)
|
| |
Bonus ($)
|
| |
Option awards
($)(1) |
| |
All other
compensation ($) |
| |
Total ($)
|
| ||||||||||||||||||
John Koconis,
CEO, President and Chairman |
| | | | 2020 | | | | | $ | 288,846 | | | | | $ | 140,577 | | | | | | — | | | | | $ | 77,841(2) | | | | | $ | 507,264 | | |
| | | 2019 | | | | | $ | 79,488 | | | | | $ | 50,000 | | | | | | — | | | | | $ | 150,343(3) | | | | | $ | 279,831 | | | ||
Joseph Lucchese,
CFO, Treasurer and EVP |
| | | | 2020 | | | | | $ | 176,807 | | | | | $ | 42,000 | | | | | $ | 89,321 | | | | | $ | 52,991(2) | | | | | $ | 361,119 | | |
| | | 2019 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Zachary Rome(4),
COO, EVP, Secretary and Director |
| | | | 2020 | | | | | $ | 183,928 | | | | | $ | 42,000 | | | | | | — | | | | | $ | 74,742(2) | | | | | $ | 300,670 | | |
| | | 2019 | | | | | $ | 93,750 | | | | | $ | 33,750 | | | | | | — | | | | | $ | 67,669(3) | | | | | $ | 195,169 | | | ||
Michael Derby,
Former Executive Chairman |
| | | | 2020 | | | | | $ | 134,077 | | | | | $ | 42,000 | | | | | | — | | | | | $ | 37,751(2) | | | | | $ | 213,828 | | |
| | | 2019 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Steven Bosacki,
Former CEO |
| | | | 2020 | | | | | $ | 126,215 | | | | | | — | | | | | | — | | | | | $ | 45,769(5) | | | | | $ | 171,984 | | |
| | | 2019 | | | | | $ | 163,094 | | | | | | — | | | | | $ | 21,777 | | | | | | — | | | | | $ | 184,871 | | |
| | | | | | | | |
Option awards
|
| | | | | | | | | | | | | |||||||||
Name
|
| |
Grant date
|
| |
Number of
securities underlying unexercised options (#) exercisable |
| |
Number of
securities underlying unexercised options (#) unexercisable |
| |
Option
exercise price ($) |
| |
Option
expiration date |
| |||||||||||||||
John Koconis
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Joseph Lucchese
|
| | | | 6/8/2020 | | | | | | — | | | | | | 97,083(1) | | | | | | 2.87 | | | | | | 6/7/2030 | | |
Zachary Rome
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Michael Derby
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Steven Bosacki
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name
|
| |
Number of Shares
Underlying Unexercised VARs |
| |
Expiration
Date |
| ||||||||||||
|
Exercisable
|
| |
Unexercisable
|
| ||||||||||||||
John Koconis
|
| | | | 42,181 | | | | | | 167,466 | | | | | | 7/1/2029 | | |
Joseph Lucchese
|
| | | | — | | | | | | — | | | | | | — | | |
Zachary Rome
|
| | | | 52,884 | | | | | | 79,326 | | | | | | 3/1/2029 | | |
Michael Derby
|
| | | | — | | | | | | — | | | | | | — | | |
Steven Bosacki
|
| | | | — | | | | | | — | | | | | | — | | |
Name
|
| |
Fees Earned
or Paid in Cash ($) |
| |
Stock
Awards ($) |
| |
Option
Awards ($)(1) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| |||||||||||||||
David Cohen, M.D.
|
| | | $ | 11,500 | | | | | | — | | | | |
|
(2)
|
| | | | | — | | | | | $ | 11,500 | | |
Lubor Gaal, Ph.D.
|
| | | $ | 10,000 | | | | | | — | | | | |
|
(2)
|
| | | | | — | | | | | $ | 10,000 | | |
Gianluca Pirozzi, M.D., Ph.D.
|
| | | $ | 15,000 | | | | | | — | | | | | $ | 16,008(3) | | | | | | — | | | | | $ | 31,008 | | |
Edward J. Sitar
|
| | | $ | 19,500 | | | | | | — | | | | | $ | 16,008(3) | | | | | | — | | | | | $ | 35,508 | | |
Name of Beneficial Owner(1)
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage of
Shares Beneficially Owned (%) |
| ||||||
5% or Greater Stockholders: | | | | | | | | | | | | | |
TardiMed Sciences LLC(2)
|
| | | | 5,538,271 | | | | | | 15.07% | | |
Altium Capital Management LP(3)
|
| | | | 6,085,289 | | | | | | 9.99% | | |
Empery Asset Management, LP(4)
|
| | | | 10,132,654 | | | | | | 9.99% | | |
Hudson Bay Capital Management LP(5)
|
| | | | 1,949,834 | | | | | | 5.05% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
John Koconis(6)
|
| | | | 84,362 | | | | | | * | | |
Joseph Lucchese(7)
|
| | | | 34,386 | | | | | | * | | |
Zachary Rome(8)
|
| | | | 52,884 | | | | | | * | | |
Edward J. Sitar(9)
|
| | | | 6,608 | | | | | | * | | |
Gianluca Pirozzi(10)
|
| | | | 6,068 | | | | | | * | | |
David Cohen
|
| | | | — | | | | | | — | | |
Lubor Gaal
|
| | | | — | | | | | | — | | |
Michael Derby(2)
|
| | | | 5,538,271 | | | | | | 15.07% | | |
Steven Bosacki
|
| | | | — | | | | | | — | | |
All Executive Officers and Directors as a group (8 persons):
|
| | | | 184,848 | | | | | | 5.02% | | |
Name and Position
|
| |
Dollar
Value |
| |
Number of
Awards(1) |
| ||||||
Alan Mendelsohn, M.D.
|
| | |
|
(2)
|
| | | | | 347,991 | | |
Lubor Gaal, Ph.D.
|
| | |
|
(2)
|
| | | | | 71,893 | | |
David Cohen, M.D.
|
| | |
|
(2)
|
| | | | | 71,893 | | |
Gianluca Pirozzi, M.D., Ph.D.
|
| | |
|
(2)
|
| | | | | 47,623 | | |
Edward J. Sitar
|
| | |
|
(2)
|
| | | | | 47,623 | | |
All current executive officers as a group
|
| | |
|
(2)
|
| | | | | 347,991 | | |
All current directors who are not executive officers as a group
|
| | |
|
(2)
|
| | | | | 239,032 | | |
All current employees, including current officers who are not executive officers,
as a group |
| | | | — | | | | | | — | | |
Plan category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights (a) |
| |
Weighted average
exercise price of outstanding options, warrants and rights (b) |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column a) (c)(2) |
| |||||||||
Equity compensation plans approved by security holders(1)
|
| | | | 986,614 | | | | | $ | 4.03 | | | | | | 786,377 | | |
Equity compensation plans not approved by security holders(3)
|
| | | | 87,511 | | | | | $ | 0.01 | | | | | | — | | |
Total
|
| | | | | | | | $ | | | | | | | |
Fee Category
|
| |
2020
|
| |
2019
|
| ||||||
| | |
(In thousands)
|
| |||||||||
Audit Fees
|
| | | $ | 544.2 | | | | | $ | 30.2 | | |
Audit-Related Fees
|
| | | $ | — | | | | | $ | — | | |
Tax Fees
|
| | | $ | — | | | | | $ | — | | |
All Other Fees
|
| | | $ | — | | | | | $ | — | | |
Total Fees
|
| | | $ | 544.2 | | | | | $ | 30.2 | | |
| | | | TIMBER PHARMACEUTICALS, INC. | |
| | | |
By:
Name:
Title: |
|